Video

Zanubrutinib plus Obinutuzumab versus Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study

Author(s):

Christopher Flowers, MD

Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.

Related Videos
Shella Saint Fleur-Lominy, MD, PhD
Manali Kamdar, MD
A Phase 0/1 ‘trigger’ trial of BDTX-1535 in recurrent high-grade glioma (HGG) patients with EGFR alterations or fusions
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Sattva S. Neelapu, MD
Sattva S. Neelapu, MD
Julie M. Vose, MD, MBA
Lakshmi Nayak, MD
John Burke, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Related Content
The FDA has approved blinatumomab (Blincyto) for the treatment of adult and pediatric patients aged 1 month or older who have CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia in the consolidation phase, irrespective of measurable residual disease status.
June 14th 2024

FDA Approves Blinatumomab for CD19+ B-ALL in the Consolidation Phase

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Josep-Maria Ribera MD, PhD
June 14th 2024

Ponatinib Regimen Shows Long-term Efficacy in Acute Lymphoblastic Leukemia

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Haifa Kathrin Al-Ali, MD
June 14th 2024

Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis

Ibrahim T. Aldoss, MD
June 14th 2024

CD7-Directed CAR T-Cell Therapy WU-CART-007 Is Safe in R/R T-ALL/LBL